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OBJECTIVE: To analyze major histocompatibility complex expression in the muscle fibers of juvenile and adult
dermatomyositis.
METHOD: In total, 28 untreated adult dermatomyositis patients, 28 juvenile dermatomyositis patients (Bohan and
Peter’s criteria) and a control group consisting of four dystrophic and five Pompe’s disease patients were analyzed.
Routine histological and immunohistochemical (major histocompatibility complex I and II, StreptoABComplex/HRP,
Dakopatts) analyses were performed on serial frozen muscle sections. Inflammatory cells, fiber damage, perifascicular
atrophy and increased connective tissue were analyzed relative to the expression of major histocompatibility
complexes I and II, which were assessed as negatively or positively stained fibers in 10 fields (200X).
RESULTS: The mean ages at disease onset were 42.0¡15.9 and 7.3¡3.4 years in adult and juvenile dermatomyositis,
respectively, and the symptom durations before muscle biopsy were similar in both groups. No significant
differences were observed regarding gender, ethnicity and frequency of organ involvement, except for higher
creatine kinase and lactate dehydrogenase levels in adult dermatomyositis (p,0.050). Moreover, a significantly
higher frequency of major histocompatibility complex I (96.4% vs. 50.0%, p,0.001) compared with major
histocompatibility complex II expression (14.3% vs. 53.6%, p= 0.004) was observed in juvenile dermatomyositis.
Fiber damage (p= 0.006) and increased connective tissue (p,0.001) were significantly higher in adult
dermatomyositis compared with the presence of perifascicular atrophy (p,0.001). The results of the histochemical
and histological data did not correlate with the demographic data or with the clinical and laboratory features.
CONCLUSION: The overexpression of major histocompatibility complex I was an important finding for the diagnosis
of both groups, particularly for juvenile dermatomyositis, whereas there was lower levels of expression of major
histocompatibility complex II than major histocompatibility complex I. This finding was particularly apparent in
juvenile dermatomyositis.
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INTRODUCTION
Idiopathic inflammatory myopathies are a heterogeneous
group of autoimmune diseases and include dermatomyosi-
tis (DM), polymyositis, and inclusion body myositis. These
myopathies differ in regard to their clinical, histological,
and immunopathological features (1-3).
The incidence of DM is 5-10 cases per million per year,
with the adult form of the disease primarily affecting
individuals between 45 and 55 years old, whereas the
pediatric form affects children and adolescents between 5
and 10 years old. DM is twice as common in women as in
men, with no ethnic predilection (4).
With respect to the immunopathological analysis, the
expression of major histocompatibility complex (MHC) I on
target cells is a prerequisite for antigen-specific T cell-
mediated cytotoxicity (5). Normal muscle fibers do not
express this complex (6,7), but it is overexpressed in
inflammatory myopathies (8-11).
MHC I overexpression in muscle fibers in early juvenile
DM (JDM) without therapy and even in the absence of
lymphocytic infiltration and muscle damage has been
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reported (12). Moreover, we have recently shown that MHC
I overexpression in muscle fibers is both a premature and
late marker of JDM regardless of the evolution time of
disease, glucocorticosteroid therapy and the grading of
inflammation by clinical, laboratory and histological para-
meters (13). Similarly, MHC I overexpression, mainly in the
perifascicular area, has been described in adult DM (ADM),
even in muscle biopsies without typical features, as
inflammatory infiltrates and perifascicular atrophy.
In contrast, MHC II is expressed on antigen-presenting
cells and is necessary to activate T helper lymphocytes and
to initiate an immune response. It is not usually expressed
on normal myofibers (7) but is expressed on myoblasts in
culture (14) that behave as antigen-presenting cells (15).
However, the actual function of MHC II in inflammatory
myopathies remains controversial in the literature.
MHC I and II have been studied in ADM and JDM
patients, although not systematically and simultaneously.
Therefore, the aim of this study was to assess the expression
of this class of proteins comparatively in ADM and JDM
muscle biopsies and to describe the possible MHC expres-
sion mechanism(s) involved in both groups.
MATERIALS AND METHODS
In total, 28 JDM and 28 ADM consecutive patients
fulfilling Bohan & Peter’s criteria (3) were included in this
study. The patients were followed between 1990 and 2010 in
the Pediatric Rheumatology Unit of the Children’ Institute
and the Inflammatory Myopathies Unit of the Hospital das
Clı´nicas da Faculdade de Medicina da Universidade de Sa˜o
Paulo. As a control group, we included nine muscle biopsies
of the following patients: two with limb-girdle muscular
dystrophy (27 and 40 years-old, with immunohistochemical
studies), two with facio-scapular-humeral dystrophy (20
and 51 years-old, with molecular confirmations) and five
with Pompe’s disease (ages of 2 years 1 month, 2 years 11
months, 11 years 10 months, 19 years 6 months and 43 years,
with molecular diagnoses). No patients or controls had
evidence of an associated malignancy.
The study was approved by the local research ethics
committee of our university hospital.
None of the ADM and JDM patients had a malignancy. The
demographics, clinical manifestations at disease onset (cuta-
neous involvement: heliotrope and Gottron’s papule; heart
involvement: myocarditis and acute myocardial infarct;
gastrointestinal tract involvement: dysphagia; articular invol-
vement: arthralgia and/or arthritis; and pulmonary involve-
ment: pulmonary alterations in computer tomography and
symptoms such as dyspnea) and laboratory data were obtain-
ed through a systematic review of the patient records. Limb
muscle strength was graded according to the Medical
Research Council as the following: grade 0, absence of muscle
contraction; grade I, slight signs of contractility; grade II,
movements of normal amplitude but not against the action of
gravity; grade III, normal range of motion against gravity;
grade IV, full mobility against gravity and degree of resis-
tance; and grade V, complete mobility and strong resistance
against the action of gravity (16).
The laboratory data corresponded to information col-
lected at disease onset. Creatine kinase (normal range: 24-
173 IU/L), lactate dehydrogenase (20-350 IU/L), amino-
transferase alanine (10-36 IU/L), aminotransferase aspartate
(10-36 IU/L) and aldolase (1.0-7.5 IU/L) were determined
by the automated kinetic method.
Muscle biopsies of the brachial biceps were routinely
performed on the same day as the laboratory exams.
Sequential frozen sections were first stained for hematox-
ylin-eosin (HE) and then by immunohistochemistry. Each
muscle biopsy specimen was coded and analyzed separately
by two investigators (SKS and AMES), who were blinded to
the diagnosis and clinical status. When any discrepancy
was noted, the sample was reviewed concomitantly. Fiber
damage, inflammatory infiltrate, perifascicular atrophy and
increased connective tissue were assessed semi-quantitatively
as absent, minimal, moderate or intense. A visual ana-
log scale (VAS) was also included to score the global degree of
abnormality from 0 (no abnormality) to 10 (most abnormal).
Monoclonal antibodies (Dakopatts, Glostrup, Denmark)
against MHC I and II were used at dilutions of 1:100. The
StreptABComplex/HRP immunohistochemical procedure
was performed as follows. Serial frozen sections of 5 mm
thickness were fixed for 10 minutes in acetone at 4 C˚.
Figure 1 -Major histocompatibility complex I and II expression in muscle fibre membrane surface of juvenile and adult dermatomyositis.
Notes: The immunohistochemistry analysis demonstrates significantly higher major histocompatibility complex I expression in fibres of
juvenile dermatomyositis compared to adult dermatomyositis, in contrast to major histocompatibility complex II expression.
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Endogenous peroxidase was blocked with 1% H2O2 in
absolute methanol three times for 10 minutes. After a rinse
in phosphate-buffered saline (PBS 0.01 M, pH 7.4) for 5
minutes, the specimen was incubated in fetal bovine serum in
a wet chamber for 1 hour at 37 C˚. The primary antibody,
diluted in PBS and 1% BSA, was applied in a wet chamber at
37 C˚ overnight. The slides were then washed in PBS, and the
prepared secondary mouse biotinylated antibody (StreptAB
Complex/HRP) was applied for 30 minutes at 37 C˚, followed
by rinsing in PBS. Subsequently, the prepared StreptAB
Complex/HRP complex at a 1:100 dilution was applied for 30
minutes at 37 C˚, and after rinsing in PBS, the slides were
incubated with a chromogenic substrate solution for perox-
idase 3,39-diaminobenzidine tetrahydrochloride solution, a
chromogenic substrate for peroxidase. After a final rinse,
hematoxylin counterstaining was performed. The slides were
mounted and cover-slipped with an aqueous-based mount-
ing medium. The preparations of all muscle specimens were
performed at the same time as a batch. Under 200X
magnification, 10 random fields, representing almost the
entire area of the specimen and including an average of 500-
1000 muscle fibers, were analyzed.
The immunohistochemical preparations were analyzed for
the expression levels of MHC I and II using a semi-quantitative
method: (-) = positively stained muscle fibers were absent;
(+) = 1 to 10% positively stained fibers; (++) = 11 to 25%
positively stained fibers; (+++) = 26 to 50% positively stained
fibers; and (++++) = 51 to 100% positively stained fibers.
The results were expressed as means¡standard devia-
tions (SD) or percentages. The chi-square and Student‘s
t-tests were employed for non-parametric and parametric
values, respectively. The 95% confidence interval (95% CI)
of the percentages was calculated using a binomial
distribution. The age- and disease duration-adjusted odds
ratios (OR) and 95% CI were calculated based on an
unconditional logistic model. These calculations were
performed using the STATA version 7.0 (STATA, College
Station, TX, USA) computer program. A p-value,0.05 was
considered to be statistically significant.
RESULTS
The demographic, clinical and laboratory features are
shown in Table 1. The ages at disease onset were 42.0¡15.9
and 7.3¡3.4 years of age in ADM and JDM, respectively,
and the disease times before the muscle biopsy were similar
in both groups (9.4¡11.1 vs. 11.3¡16.0 months, p= 0.616).
There were no differences between the groups with respect
to the clinical and laboratory data, except for the creatine
kinase and lactate dehydrogenase levels, which were higher
in ADM than in JDM (Table 1).
In general, the immunohistochemistry analysis revealed
significantly higher MHC I-positive expression in the JDM
group compared with the ADM group (96.4% vs. 50.0%,
p,0.001). Analyzed individually, MHC I expression was
observed in more than 50% (4+) of the fibers in four (14.3%)
JDM cases, in up to 25% (2+) of the fibers in five (17.8%)
cases, and in up to 50% (3+) of fibers in three (10.7%) cases.
In 15 (53.6%) cases, MHC I was expressed in less than 10%
(1+) of the fibers (Table 2). Of note, negative MHC I
expression was observed in only one patient. In contrast,
MHC I was positive in only half of the ADM cases, with 10
(35.7%) having more than 50% (4+) positive fibers. Scores of
1+ and 3+ were observed in one (3.6%) case each, whereas a
Table 1 - Clinical and laboratory features of adult and juvenile dermatomyositis.
Features ADM (n=28) JDM (n=28) p-value
Age at disease onset¡SD (years) 42.0¡15.9 7.3¡3.4
Disease duration¡SD (months) 9.4¡11.1 11.3¡16.0 0.616
Gender: female (%) 24 (85.7) 20 (71.4) 0.193
Constitutional symptoms (%) 14 (50.0) 11 (39.3) 0.420
Cutaneous involvement
Heliotrope (%) 26 (92.9) 21 (75.0) 0.127
Gottron‘s papule (%) 28 (100.0) 22 (78.6) 0.313
Heart involvement (%) 0 3(10.7) 0.075
Gastrointestinal tract involvement (%) 0 2 (7.1) 0.150
Articular involvement (%) 11 (39.3) 8 (28.6) 0.397
Pulmonary involvement (%) 7 (25.0) 3 (10.7) 0.163
Muscle strength
Upper limbs
Grade I (%) 0 0 0.945
Grade II (%) 3 (10.7) 3 (10.7)
Grade III (%) 11 (39.3) 12 (42.9)
Grade IV (%) 12 (42.9) 12 (42.9)
Grade V (%) 2 (7.1) 1 (3.5)
Lower limbs
Grade I (%) 0 0 0.774
Grade II (%) 4 (14.3) 5 (17.8)
Grade III (%) 11 (39.3) 11 (29.3)
Grade IV (%) 12 (42.9) 12 (42.9)
Grade V (%) 1 (3.5) 0
Laboratory alterations
Creatine kinase¡SD (IU/L) 3820.9¡5332.3 0.030 171.4¡400.8
Lactate dehydrogenase¡SD (IU/L) 1105.7¡ 1321.6 200.7¡254.4 0.863
Aspartate aminotransferase¡SD (IU/L) 0.020 174.0¡366.1 56.5¡103.6
Alanine aminotransferase¡SD (IU/L) 1665.0¡1311.2 0.807 16.7¡7.7
Aldolase¡SD (IU/L) 937.8¡552.1 192.5¡305.1 0.329
ADM: adult dermatomyositis; JDM: juvenile dermatomyositis; SD: standard deviation.
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score of 2+ was detected in two cases (7.1%) (Table 2). Figure
1 shows comparative representatives of the DMJ and DM
biopsies. In the control group, only one patient with facio-
scapular humeral dystrophy was positive for MHC I, with
less than 10% expression (1+).
The percentage of MHC II expression was significantly
higher in ADM than in JDM (50.0% vs. 14.3%, p= 0.004). In
contrast, all patients in the control group were negative for
MHC II.
Inflammatory cell infiltration was detected in 26 out of
28 (92.9%) JDM muscle biopsies and in the majority of
perifascicular atrophy patients (27, 96.4%) (Table 2).
Additionally, minimal alterations in muscle fiber damage
were observed in 15 (53.6%) patients, and only a slight
increase in connective tissue was observed in two (7.1%)
patients. Rimmed vacuoles were not detected in any biopsy.
Compared with JDM, inflammatory cell infiltration was
observed in 22 (78.6%) ADM muscle specimens (p = 0.384).
In contrast, fiber damage and increased connective tissue
was observed in 23 (82.1%) ADM cases for both parameters,
with significant differences between JDM and ADM
(p= 0.006 and p,0.001, respectively). Interestingly, perifas-
cicular atrophy was observed in only 14 (50.0%) ADM
patients (p,0.001).
The overview of the histopathological findings was
graded using a VAS and was similar between the two
groups (p= 0.748). Following the result pattern of the
analyses of the individual histological parameters, the
VAS was not correlated with the clinical parameters
measuring disability, including limb muscle strength.
Neither MHC I nor MHC II expression correlated with the
interval of disease evolution to the biopsy, the age at disease
onset, the grading of muscle strength, the creatine kinase
level or any other clinical manifestation in either ADM and
JDM (Table 3). Moreover, these proteins were not correlated
with any of the histological parameters (inflammatory cell
infiltration, fiber damage, perifascicular atrophy and con-
nective tissue proliferation) in either group (p.0.050).
DISCUSSION
Our study showed that MHC I and II were expressed in
the muscle fibers of JDM and ADM, two idiopathic
inflammatory myopathies, with a distinct pattern: there
was greater MHC I expression in JDM and greater MHC II
expression in ADM. These findings were observed regard-
less of the clinical, laboratory or histological features.
The major strengths of this study were the stringent
inclusion of untreated patients who fulfilled Bohan &
Peter‘s criteria (3) for DM, the analysis of only one type of
skeletal muscle, the use of standardized histological,
histochemical and immunohistochemical processing meth-
ods, and the double-blind analyses by two independent
investigators, which assured the homogeneity of the studied
parameters and consistency of the results.
The presence of inflammatory cells in the skeletal muscle
biopsy in conjunction with the clinical and laboratory
features resulted in the diagnosis of an inflammatory
myopathy. However, the muscle biopsy findings may be
non-specific or even normal, and in such cases, the
diagnosis of inflammatory myopathy and, consequently,
Table 2 - Immunohistological and histological analyses of
muscle biopsies from untreated adult and juvenile
dermatomyositis patients.
ADM JDM p-value
(n= 28) (n = 28)
MHC in muscle fibers
Class I expression (%) 14 (50.0) 1 (3.6) ,0.001
- 1 (3.6) 15 (53.6)
+ 2 (7.1) 5 (17.8)
++ 1 (3.6) 3 (10.7)
+++ 10 (35.7) 4 (14.3)
++++
Class II expression (%) 13 (46.4) 24 (85.7) 0.004
- 1 (3.6) 2 (7.1)
+ 2 (7.1) 1 (3.6)
++ 1 (3.6) 0
+++ 10 (35.7) 1 (3.6)
++++
Histological analysis in
muscle fibers
14 (50.0) 27 (96.4) ,0.001
Perifascicular atrophy 0.384
Inflammatory infiltration
(%)
6 (21.4) 2 (7.1)
Absent 14 (50.0) 17 (60.7)
Minimum 6 (21.4) 5 (17.9)
Moderate 2 (7.2) 4 (14.3) 0.006
Intense
Fiber damage (%) 5 (17.9) 13 (46.4)
Absent 14 (50.0) 15 (53.6)
Minimum 4 (14.2) 0
Moderate 5 (17.9) 0 ,0.001
Intense
Increased connective
tissue (%)
5 (17.9) 26 (92.9)
Absent 15 (53.6) 2 (7.1)
Minimum 6 (21.4) 0
Moderate 2 (7.1) 0
Intense
VAS 3.0 (0-9) 3.5 (1-8) 0.748
Median (range)
ADM: adult dermatomyositis; JDM: juvenile dermatomyositis; MHC: major
histocompatibility complex; VAS: visual analog score.
Fiber damage, inflammatory infiltrate and increased connective tissue
were assessed semi-quantitatively as absent, minimal, moderate or
intense.
The expression levels of MHC I and II were assessed by a semi-quantitative
method: (-) = positively stained endothelial cells only; (+) = 1 to 10%
positively stained fibers; (++) = 11 to 25% positively stained fibers;
(+++) = 26 to 50% positively stained fibers; and (++++) = 51 to 100%
positively stained fibers.
Table 3 - Relationship among various myositis parameters
and the MHC I / II presence in dermatomyositis.
Parameters ADM (n=28) JDM (n=28)
MHC I MHC II MHC I MHC II
Interval of disease to
biopsy
0.807 0.807 0.787 0.515
Age at onset 0.086 0.086 0.296 0.767
Degree of muscle strength 0.251 0.0251 0.179 0.484
Creatine kinase level 0.362 0.362 1.000 0.141
Other clinical
manifestations
.0.050 .0.050 .0.050 .0.050
Perifascicular atrophy 0.257 0.257 1.000 1.000
Fiber damage 0.045 0.045 0.464 1.000
Increased connective tissue 0.537 0.537 1.000 1.000
Inflammatory cell
infiltration
0.512 0.512 1.000 0.253
ADM: adult dermatomyositis; JDM: juvenile dermatomyositis; MHC: major
histocompatibility complex. Data indicate p-values.
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the therapeutic approach might be delayed. MHC protein
expression analysis by immunohistochemistry has proven
to be extremely helpful in these cases as an additional
diagnostic tool (2,11,17).
In fact, in this study, MHC I expression was present in all
JDM cases except for in one patient, who had a muscle
biopsy showing perifascicular atrophy and minimal inflam-
matory cell infiltration without fiber damage. The over-
expression of MHC I has been previously described by
others (11,12,18-20), even in muscle biopsies reported as
normal by conventional histology. In our study, 66.7% of the
MHC I-positive JDM cases presented no (7.4%) or very low
(59.3%) inflammatory cell infiltration in the analyzed muscle
specimen. In contrast, MHC I overexpression was identified
in only half of the ADM patients in our series. The
previously reported frequency of MHC I positivity has
been quite variable, ranging from 53.3% to 100% (11,17-
19,21,22). The smaller number and heterogeneity of pre-
viously studied cases may partially explain these discre-
pancies. Similarly, MHC I expression was detected in half of
the ADM cases, including cases presenting no or only
scattered inflammatory cell infiltration in the muscle biopsy
(14.3% and 42.9% of the cases, respectively). Therefore, the
positive MHC I expression in such histologically near-
normal cases proved to be a powerful tool to establish the
diagnosis of inflammatory myopathy in combination with
the compatible clinical and laboratorial findings, mainly in
the JDM cases. The MHC II expression was present in fewer
of our cases; it was observed in 50.0% and 14.3% of the
ADM and JDM cases, respectively. Variable frequencies,
ranging from 0% to 28.6%, have been reported in other
studies (17,19,21).
Whether the MHC complex up-regulation in DM results
from a nonspecific response to muscle degeneration and
regeneration or from a specific disease process is not fully
understood. Highly expressed pro-inflammatory cytokines
in DM (21,23), such as INFc and TNFa, have been reported
to induce MHC I expression in in vitro assays (24,25). The
overexpression of the MHC complex might also be second-
ary to the diffusion of secreted cytokines by inflammatory
cells near the biopsied muscle area, as up-regulation of
interleukin-1 might even reflect a stress response secondary
to the early ischemic injury of the muscle fibers (18,21,26).
The overexpression of MHC I and II in the muscle
biopsies proved to be an independent factor of not only the
duration of the disease and the degree of muscle damage
(as determined by either the degree of muscle strength
recorded during clinical examination or the muscle enzy-
matic measurements) but also the muscle histological
findings. In fact, despite the absence of inflammatory cell
infiltrates and/or perifascicular atrophy, MHC I and/or II
overexpression was clearly detected in the muscle biopsies
from patients with clinical features of DM, as demonstrated
in this study and in other studies (11,18,20-22,27). Moreover,
in our previous study, MHC I expression was independent
of even corticosteroid therapy administered prior to the
muscle biopsy (13).
Our results indicated that MHC I is overexpressed in the
muscle biopsies of JDM and ADM patients. MHC I- and II-
dependent processes require the expression of ICAM-1. The
ICAM-1 molecule is necessary to stabilize the interactions
between the cell receptor and the MHC-peptide complex
in antigen recognition (28). The ICAM-1 molecule, which
is essential for cell adhesion, also triggers the cytotoxic
mechanism. The results of this study combined with our
previous observation of differential positive ICAM-1 expres-
sion in the muscle fibers of ADM, in contrast to the increased
expression of ICAM-1 in the muscle vessels of JDM (29),
corroborates the myocytotoxic mechanism in adult inflam-
matory myopathies, in contrast to muscle lesions through the
involvement of microvasculature in JDM.
The limitation of this study is inherent to the applied
immunohistochemistry method, in which absolute quanti-
tative data are difficult to obtain. However, the semiquanti-
tative analysis performed by two independent investigators
and based on microscopic fields chosen with uniform
criteria, along with the staining of specimens performed in
a single batch, were the strategies adopted to minimize bias.
The analyses of these expression profiles in the context of
the clinical evolution, therapy response, and the results of
other complementary exams (such as capillaroscopy), along
with comparisons to other inflammatory myopathies (such
as polymyositis and inclusion body myositis), may improve
our understanding of the pathophysiology of these diseases.
In summary, JDM patients presented more MHC I
positivity and perifascicular atrophy and less fiber damage,
connective tissue proliferation and increased creatine kinase
/ lactate dehydrogenase levels compared with ADM
patients. Immunohistochemical analysis of MHC I and
II in muscle biopsies is confirmed as a complementary
diagnostic tool for inflammatory myopathy, particularly
with respect to the overexpression of MHC I in JDM cases.
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